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Abstract
Though remissions have been observed following allo-HSCT for the treatment of CLL, many CLL patients are ineligible for
transplant due to the lack of HLA-compatible donors. The use of umbilical cord blood (UCB) permits transplantation of
many patients who lack HLA-compatible donors due to reduced requirements for stringent HLA matching between graft
and recipient; however, disease relapse remains a concern with this modality. The generation of CLL-specific CTL from UCB
T-cells, primed and expanded against the leukemic clone, might enhance the GVL effect and improve outcomes with UCB
transplantation. Here we report the generation of functional, CLL-specific CTL using CD40-ligated CLL cells to prime
partially-HLA matched UCB T-cells. Functionality and specificity were demonstrated by immune synapse assay, IFN-c
ELISpot, multi-parametric intracellular cytokine flow cytometry, and 51Cr release assay. The use of patient-specific, non-CLL
controls demonstrated the generation of both alloantigen and CLL-specific responses. Subsequently, we developed a
clinically-applicable procedure permitting separation of alloreactive CTL from leukemia-specific CTL. Leukemia-specific CTL
were able to mediate in vivo killing of CLL in humanized mice without concurrent or subsequent development of
xenoGVHD. Our results demonstrate that generation of CLL-specific effectors from UCB is feasible and practical, and the
results support further exploration of this strategy as a treatment modality for CLL.
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Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most prevalent
of the adult leukemias, accounting for at least 180,000 new
diagnoses worldwide every year [1]. While CLL is effectively
treated with a variety of chemotherapeutic or antibody-based
regimens, it is a chronic disease and cure is not achieved with
conventional chemotherapy [2]. There is clear evidence that a
graft versus leukemia (GVL) effect exists in CLL [3]; [4], and a
number of studies have successfully demonstrated durable
remissions following allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT) for poor-risk, relapsed, or refractory CLL [5];
[6]. Umbilical cord blood (UCB) is being used with increasing
frequency as a stem cell source for allotransplant among patients
lacking HLA-compatible donors. In spite of successful outcomes
following allo-HSCT, disease relapse remains a significant
contributor to post-transplant mortality in patients with CLL.
Accordingly, a number of strategies have been employed in an
effort to amplify and perpetuate GVL in conjunction with allo-
HSCT including the use of rituximab [7], non-myeloablative
reduced-intensity conditioning regimens, and donor lymphocyte
infusion (DLI) [4]–[8].
Consistent with a GVL affect, CLL cells are known to express a
variety of tumor-associated antigens (TAA) that distinguish CLL
from non-neoplastic cell types. Patient-specific idiotype determi-
nants, fibromodulin, MDM2, survivin, and KW-13 are some of
the CLL-specific antigens against which cellular immune responses
are known to be directed [9]–[13], and a variety of different
strategies have been employed to exploit the existence of a disease-
specific antigenic profile [14]–[16]. One promising approach
attempted clinically involved vaccination of patients with autolo-
gous CLL cells engineered to express CD154 (CD40L) [17]. The
engagement of CD40 by its ligand on the surface of CLL cells
upregulates many costimulatory molecules, thereby transforming
the CLL cells into antigen-presenting cells (APCs) capable of
stimulating CLL-specific T-cell responses [17]–[19]. Though this
strategy produced detectable clinical responses, such responses
were typically short-lived. The transient nature of a T-cell
approach was not wholly unexpected given the well-documented
ability of CLL to suppress T-cell function [20]–[22]. Recent work
by our group has demonstrated that umbilical cord blood (UCB)
T-cells may have some capacity to overcome immunosuppressive
affects typically exerted by CLL [23]. While the precise
mechanism of this phenomenon is not completely understood,
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e51390
these observations led to the hypothesis that partially-HLA
matched UCB T-cells might be able to mediate specific
recognition and killing of CLL. The generation of such CLL-
specific T-cells from cord blood could be of significant clinical
benefit either in the setting of UCB transplantation or as a third
party T cell therapy after matched-related or matched-unrelated
donor HSCT. While far greater experience exists with traditional
stem cell sources for patients with CLL, there is mounting
evidence that UCB transplant for CLL is feasible and comparable
to traditional graft sources, even with reduced-intensity condition-
ing regimens [24]; [25].
Materials and Methods
Ethics statement
All animal work was performed under an MDACC IRB
approved animal protocol. All mice were euthanized under
anesthesia by cervical dislocation and experienced no pain or
suffering. All patient samples were made available for research use
under an MDACC IRB approved clinical protocol with informed,
written consent of the patient. All umbilical cord blood samples
were made available for research use under MDACC IRB
approved protocols LAB02-630 and LAB03-796 with informed,
written consent of the mother.
Generation of CLL-APC
CLL APCs were generated from peripheral blood lymphocytes
of CLL patient samples donated under an IRB-approved protocol.
CLL peripheral blood mononuclear cell (PBMC) samples used in
these experiments consisted of 80–99% CLL cells as determined
by CLIA-compliant clinical flow cytometry. Patient PBMCs were
separated from red cells on a Ficoll gradient and cryopreserved.
Upon thawing, patient PBMCs were resuspended at 26107/ml in
AIM-V medium (Invitrogen, Carlsbad, CA). Cells were then
transduced with an adenoviral construct encoding murine CD40L
(mCD154, surface stable on human cells) [17] by a 1:1 incubation
of cells and virus at 37uC for 48 hours. Transduction and
subsequent ligation of CD40 was verified by monitoring expres-
sion of mCD154 and upregulation of CD95 and/or CD80 by flow
cytometry. Transduced CLL-APC were c-irradiated at 3,000 cGy.
Priming and Expansion of Partially-HLA matched UCB T-
cells
Partially HLA matched (at least 4/6 of HLA-A, B, and DR loci)
non-adherent UCB lymphocytes were incubated 5:1 with CLL-
APC in RPMI-1640 (Invitrogen) supplemented with 10% human
AB serum (Gemini Bioproducts, West Sacramento, CA), 2 mM l-
glutamine (Invitrogen), and 1% Antibiotic/Antimycotic (Invitro-
gen). After four days, cultures were supplemented with 100 U/ml
IL-2 (Chiron, Emeryville, CA), 10 ng/ml IL-7 (R&D Systems,
Minneapolis, MN), and 5 ng/ml IL-15 (R&D Systems), and
resupplemented with fresh cytokines every 2 days thereafter. IL-7
and IL-15 were only supplied during the first 10 days of expansion.
Expanding UCB lymphocytes were restimulated with cryopre-
served CLL-APC 7–10 days after the primary stimulation and
another 7–10 after the secondary stimulation. Expanded UCB
cells were generated against 14 different combinations of UCB
units and CLL patient samples.
Immunoassays
IFN-c ELISpot and 51Cr release assays were performed as
previously described [26] using non-CD40 ligated CLL cells as
targets, expanded CD8+ cells isolated from the same CLL patient
sample (alloantigen control targets), and K562 cells (NK cell
activity controls). E:T ratios are reported at 20:1 unless otherwise
indicated. CD8+ cells were obtained by isolation and expansion of
patient CD3+ with anti-CD3/anti-CD28 beads (Invitrogen)
followed by depletion of CD4+ cells with magnetic beads
(Miltenyi-Biotec, Auburn, CA). Expansion of CD8+ cells with
anti-CD3/anti-CD28 beads generates CD8+ cells with an
activated phenotype. In HLA blocking experiments, MHC class
I-mediated lysis was blocked using the W6/32 pan-class I blocking
antibody (Dako, Carpinteria, CA) at a dilution of 50:1 (3.5 mg/ml).
Immune synapse assay was performed as previously described [27]
using unmanipulated CLL cells as targets. Multiparametric
intracellular cytokine and surface marker flow cytometry assays
were performed as previously described [26]. TCR Vb spectratyp-
ing was performed as previously described [28].
In Vitro Separation of GVH from GVL
Bulk T-cell products stimulated twice previously with CLL-APC
were cultured with c-irradiated, bead-expanded CD8+ cells
derived from the same CLL patient as were the APC. After
24 hours co-culture, the T-cell product was CD25-depleted by
magnetic separation using either a research-grade strategy (anti-
CD25/biotin primary [Biolegend, San Diego, CA] followed by
anti-biotin microbeads [Miltenyi-Biotec]) or a GMP-compliant
strategy (anti-CD25 microbeads [Miltenyi-Biotec]). Subsequently,
the CD25-negative fraction was stimulated a third time with CLL-
APC and subsequently characterized by immunoassay.
In Vivo Modeling
Humanized NOD/scid/IL-2Rc2/2 (NSG) mice were engrafted
with CLL as described previously [29]. Briefly, NSG mice were
irradiated at 320 cGy after which they were humanized by i.v.
administration of 1.56105 CD34-selected umbilical cord blood
cells. Mice were bled every two weeks and analyzed by flow
cytometry to monitor for the emergence of human CD3+ T-cells.
Upon detection of T-cells, mice were engrafted with 56106 CFSE-
labeled CLL cells. Engrafted CLL was derived from the same
clone as was used to generate CLL-APC for expansion of UCB-
CTL. Allogeneic interaction between UCB-derived T-cells and the
few T-cells that accompany the CLL graft is hypothesized to
produce the cytokines necessary for CLL engraftment [26].
Following verification of CLL engraftment by CFSE dilution (1–
2 weeks post-administration of the CLL graft), engrafted mice
received a single injection of 56106 CLL-specific CTL i.v. B-cell
content of engrafted mice was monitored over the next six weeks
by flow analysis of blood, spleen, and marrow by staining with
anti-CD5, CD19, CD23, and CD45.
Statistical Analysis
Statistical differences were calculated by Student’s unpaired
two-tailed t-test unless stated otherwise. Significance was defined
as p#0.05. Error bars in all figures =+/2SD. All experimental
observations were derived from at least nine independent
experiments unless stated otherwise.
Results
Generation of CLL APC and characterization of partially
HLA-matched UCB lymphocytes
To generate CLL-APC, patient PBMCs were transduced with
an adenoviral vector encoding murine CD154 (surface stable on
human B-cells) [17]. Figure 1A and B demonstrate that CD19+
CLL cells could be successfully transduced as demonstrated by
flow staining with anti-mouse CD154 (panels A and B).
Transduction efficiency of CLL cells was variable but generally
CLL-Specific Cord Blood CTL
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robust (average transduction efficiency= 18.0%,
range= 2.6%–44.3%, n=12; Figure 1C); however, even at
low transduction efficiencies, subsequent upregulation of CD95
was generally good due to bystander effects. Stimulation of CD40
and modulation of CLL cell phenotype were determined by flow
staining with anti-CD95 (Figures 1D, 1E, and 1F). We demon-
strated that upregulation of CD95 expression was well-correlated
with concomitant upregulation of traditional costimulatory mol-
ecules like CD80 (Figures 1G and 1H) as reported previously [17].
Transduced CLL cells were compared to both mock-transduced
cells (PBS) and cells transduced with an irrelevant adenovector,
neither of which demonstrated appreciable upregulation of CD95
or CD80 from baseline. In 11 independent experiments,
costimulatory marker expression following CD40 ligation was at
least 0.56 log-fold higher than unligated controls.
Partially-HLA matched UCB lymphocytes (typically 4/6) were
expanded by three successive stimulations with CLL-APC.
Table 1 demonstrates the expansion kinetics of nine
different UCB T-cell populations. In aggregate, lympho-
cytes underwent a 5.7+/25.5 fold expansion over a
period of 21 days. After three stimulations with CLL-APC,
the product consisted almost entirely of CD3+ cells with very few
CD32CD56+ NK cells present (Figure 2A). A majority of
expanded UCB T-cells demonstrated an upregulation of CD127
(69.3%, range 64.9%–76.6%) from undetectable pre-expansion
levels (Figure 2A), indicating a memory phenotype. CD3+ cells
averaged 36% CD8+ content (range 11%–53%, Figure 2A).
CD19+ cells were not detected in any proliferating cell population
(data not shown).
Three different expanded UCB T-cell lines were spectratyped to
assess clonality, given that a tumor might avoid a monoclonal or
oligoclonal response by selective mutation of a key antigen.
Figure 2B and 2C show a representative example of a full
spectratype analysis of the naı¨ve, unstimulated UCB lymphocyte
fraction (2B) and the same fraction following three stimulations
with CLL-APC (2C). For any Vb locus, polyclonality is indicated
by a Poisson distribution of spectral peaks. The stimulated
repertoire appeared to remain highly polyclonal, supporting a
hypothesis of retained T-cell specificity against multiple antigens.
Figure 1. Characterization of CLL-APC. Mock-treated (A) or vector-treated (B) CLL cells indicate successful transduction of CLL cells with surface
stable mCD154 (mCD40L) leading to upregulation of CD95 expression on (E) vector-treated but not (D) mock-treated CLL cells. Figure 1C graphically
represents CD154 transduction efficiency of 12 independent experiments and Figure 1F graphically represents post-transduction CD95 upregulation
of those same experiments. Error Bars =+/2SD. Upregulation of CD95 (G) was shown to correlate with upregulation of costimulatory marker CD80 (H)
following treatment with CD40L-expressing vector (unshaded area). Gray shaded area indicates cells treated with control viral vector.
doi:10.1371/journal.pone.0051390.g001
CLL-Specific Cord Blood CTL
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Table 1. Umbilical Cord Blood Lymphocyte Expansion Properties.
Patient Cord Unit HLA Matches Starting (6106 cells) Actual Max (6106 cells)
Calculated Max (6106
cells)*
1 003969 4/6 10 26 208
2 003859 4/6 10 32 256
3 004442 4/6 9 23 185
4 000741 4/6 10 46 364
4 003187 4/6 10 41 326
5 010566 4/6 (6/8) 43 135 268
6 008827 4/6 (6/8) 32 74 149
8 006481 5/6 (7/8) 44 876 2,110
9 009139 5/6 (6/8) 83 850 901
*Calculated Max extrapolates the number of cells that would have been available had an entire 20% cord fraction been used in the expansion.
doi:10.1371/journal.pone.0051390.t001
Figure 2. Characterization of UCB T-cells expanded by CLL-APC. A. UCB cell products expanded by CLL-APC consisted almost entirely of
CD3+ cells with very few contaminating CD32CD56+ cells. CD3+ cells upregulated CD127 from undetectable levels pre-stimulation, indicating a
memory phenotype. Error Bars =+/2SD. CD45RA and CD28 were also significantly downregulated among expanded T-cells. Following three
stimulations with CLL-APC, expanded UCB lymphocytes were spectratyped to determine Vb repertoire polyclonality in comparison to the naı¨ve,
unstimulated fraction. B. Vb locus spectratype distribution of naı¨ve, unstimulated lymphocytes. C. Vb locus spectratype distribution of stimulated,
expanded lymphocytes. One of seven experiments shown. Note that repertoire polyclonality is maintained.
doi:10.1371/journal.pone.0051390.g002
CLL-Specific Cord Blood CTL
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Expanded CLL-specific T-cells and the naı¨ve UCB fractions
from which they were derived were both treated with PMA/
ionomycin and analyzed by multi-parametric flow cytometry to
determine cytokine secretion profile and memory phenotype as
indicated by staining with CD28 and CD45RA. Nearly all cells
derived from naı¨ve fractions were CD28+CD45RA+ (Table 2).
Naı¨ve cells did not produce any IFN-c and only low levels of IL-2.
Interestingly, half of naı¨ve UCB CD4+ and most naı¨ve UCB CD8+
cells generated high levels of TNF-a (Figures 3A, 3C, and Table 2).
In contrast, a plurality of stimulated CLL-specific UCB T-cells
were CD282CD45RA+ (Figures 3C, 3D, and Table 2). The
number of CD282CD45RA+ cells was well-correlated with the
number of CD127+ cells. Most of the stimulated cells produced
IFN-c and high levels of IL-2. As with the naı¨ve population, about
half of the stimulated CD4+ cells produced TNF-a; however, most
of the stimulated CD8+ cells no longer generated TNF-a (3B and
3D). In each panel of Figure 3, the plots shown are representative
of five independent experiments. A summation of the data is found
in Table 2.
Figure 3. UCB T-cells stimulated by partially HLA-matched CLL-APC exhibit functional cytokine profiles and variegated memory
phenotypes. Fractions of expanded and naı¨ve T-cells were treated with PMA/ionomycin and then analyzed by seven color flow cytometry for CD28/
CD45RA memory marker expression and Th-1 cytokine expression profile (IFN-c, IL-2, and TNF-a). A. Naı¨ve CD4+ cell fraction. B. Naı¨ve CD8+ cell
fraction. C. Expanded CD4+ cell fraction. D. Expanded CD8+ cell fraction. Naı¨ve cells were almost exclusively CD28+CD45RA+ whereas expanded cells
were predominantly CD282CD45RA+. A sizeable minority of CD4+ cells retained CD28 surface expression. Blue = fraction of cells positive for all three
cytokines analyzed. Red= fraction of cells positive for two of three cytokines analyzed. Green= fraction of cells positive for one of three cytokines
analyzed. Purple = fraction of cells negative for all three cytokines analyzed.
doi:10.1371/journal.pone.0051390.g003
Table 2. Umbilical Cord Blood Lymphocyte Memory
Phenotypes.
Phenotype CD4
+ CD8+
Naı¨ve Expanded Naı¨ve Expanded
CD28+CD45RA2 4.5+/23.0% 9.4+/211.6% 0.8+/21.1% 5.0+/27.2%
CD28+CD45RA+ 94.9+/23.1% 24.9+/220.3% 98.4+/21.7% 16.0+/211.8%
CD282CD45RA+ 0.1+/20.1% 36.5+/229.7% 0.5+/20.5% 59.0+/235.5%
CD282CD45RA2 0.5+/20.3% 29.2+/233.4% 0.3+/20.4% 20.1+/227.4%
doi:10.1371/journal.pone.0051390.t002
CLL-Specific Cord Blood CTL
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UCB T-cells stimulated by partially HLA-matched CLL-APC
form functional immunological synapses and
preferentially secrete IFN-c when complexed with
unmanipulated CLL cells
CLL cells can be profoundly immunosuppressive [20]–[22], a
characteristic that has hampered previous attempts at adoptive
immunotherapy. In order to verify, as previously reported [23],
that UCB-derived CLL-primed T-cells retained immune func-
tionality and/or specificity for unmodified CLL targets, we
performed an immunosynapse assay as well as IFN-c ELISpot
assays. The formation of the immune synapse is the first step by
which targets are identified and eradicated, and previous work has
demonstrated that CLL cells can suppress the formation of
immune synapses when complexed with healthy allogeneic T-cells
[20]. As demonstrated by the experiment shown (Figure 4A), 72%
of UCB T-cells primed by CD40-ligated CLL APC retained the
ability to form f-actin immunoconjugates with unligated CLL cells.
In comparison, only 11% of naı¨ve T-cells from the same UCB
graft had the ability to form synapses with CLL cells derived from
the same donor. Figures 4B and 4C indicate a typical
immunoconjugate between a blue-labeled CLL cell and B) a
CLL-specific UCB T-cell vs. C) a naı¨ve UCB T-cell. A
representative field of CLL-specific UCB T-cells is shown in
Figure 4D with immunosynaptic conjugates boxed in white and
nonproductive conjugates boxed in red. In this representative field,
4/5 conjugates or 80% form a polarized synapse.
After two or three stimulations with CLL-APC, UCB T-cells
were cultured with unmanipulated CLL cells to determine
reactivity and specificity by IFN-c ELISpot. To determine the
specificity of the response to CLL antigens, normal CD3+
lymphocytes were isolated and expanded from the same patient
that provided the CLL, and the CD4+ population was depleted to
remove the possibility of allogeneic T regulatory cell (Treg)-
mediated suppression of immune responses. Post expansion, we
verified that the bead-activated CD3+ lymphocytes expressed
MHC class II as do physiologically-activated human CD3+ cells
(data not shown). Hence, the isolated CD3+CD42 lymphocytes
expressed the same class I and class II alloantigens as did the CLL
cells and differences in spot number between CD3+ T-lineage
control stimulators and CD19+ B-lineage CLL stimulators
represent specificity against CLL or at least against B-lineage
antigens absent from the T-lineage antigenic repertoire. We also
analyzed levels of HLA-A/B/C expression on the surface of
patient CLL and the corresponding CD8+ population. In no
instances did CLL cells express higher levels of HLA-A/B/C than
the corresponding CD8+ cells, validating the use of CD8+ cells as
appropriate alloantigen controls (data not shown). Allogeneic CLL
stimulators were also included as a control for NK cell activity. As
demonstrated by the normalized composite of 11 different
experiments (Figure 5A), CLL-primed UCB T-cells exhibited a
significant increase in IFN-c ELISpots when co-cultured with CLL
stimulators in comparison to co-culture with HLA-identical CD8+
stimulators (average of all 9 experiments: 20.3%+/221.2%,
p,0.02 by pair-wise t-test), indicating distinct, CLL–specific
(or at least B-lineage specific) responses. Other controls such as
CLL-only, CD8-only, and medium only were always devoid of
spots and have been omitted for clarity. A representative
experiment (1 of 11) is depicted in Figure 5B and the results of
all 9 experiments may be found in Table 3. In the depicted
representative experiment, CLL-primed UCB T-cells exhibited a
33% (p = 0.007) increase in IFN-c ELISpots when co-cultured
with CLL stimulators in comparison to co-culture with HLA-
identical CD8+ stimulators.
UCB T-cells stimulated by partially HLA-matched CLL-APC
preferentially kill unligated CLL cells in an HLA-A/B/C
restricted fashion
After three stimulations with CLL-APC, UCB effectors were co-
cultured with 51Cr-labeled, unmanipulated CLL targets to
determine killing ability by 51Cr release. Similar to the IFN-c
ELISpot assay, normal CD8+ lymphocytes autologous to the CLL
APC were used as alloantigen controls. Labeled K562 cells served
as controls for NK activity. Normalized data from 11
different experiments indicated that CTL killing of CLL
targets was 79% higher (55.4% vs. 31.4% at E:T=20:1)
than that of the HLA-identical control targets (p= 0.00002
by pair-wise t-test, Figure 5C), indicating a highly CLL–
specific (or B-lineage specific) response. A representative experi-
ment depicted in Figure 5D shows CLL-primed UCB T-cells
lysing 54% of labeled CLL targets versus 39% of HLA-identical
CD8+ targets, and the results of all 11 experiments may be found
in Table 4. Though IFN-c secretion was higher against CLL
targets than control targets in 7 of 9 experiments, lytic killing of
CLL targets was much higher than that of control targets in all 11
experiments. To verify that killing of targets was mediated by HLA
class I/TCR interaction, the pan-HLA-A,B,C blocking antibody
W6/32 was added to lytic assays. As demonstrated by the
experiment in Figure 5E, addition of the W6/32 antibody was
sufficient to reduce lysis of CLL targets by 73% (p = 0.00003) and
lysis of the alloantigen CD8+ control by 100% (p = 0.00006). Lysis
of allogeneic NK activity controls was unaffected by the addition
of W6/32, in total indicating that lysis of allogeneic cells was due
entirely to NK cells, that lysis of CD8+ targets was due entirely to
T-cells, and that lysis of CLL targets was due predominantly to T-
cell activity.
Adult-derived T-cells stimulated by partially HLA-
matched CLL-APC cannot preferentially kill unligated CLL
cells
Previous reports have indicated defects in the ability of adult (i.e.
non-neonatal) peripheral blood-derived T-cells to interact immu-
nologically with CLL targets in the absence of previous CD40
ligation. In other words, though the strategy of CD154 transfec-
tion and subsequent CD40 ligation has previously been used to
generate CLL-APC and CLL-specific T-cells, such T-cells have
typically been able to react only against CD154-transduced CLL
targets but not against native, unmanipulated CLL targets
[17]; [20]; [21]; [23]. In order to determine whether the use of
cord blood T-cells genuinely imparts a distinct immunological
advantage over the use of adult peripheral blood-derived T-cells,
experiments were repeated using adult peripheral blood apheresis
products matched at 4/6 HLA-A,B, or DR loci with patient CLL
cells. Execution of this experiment was technically very challeng-
ing as there were relatively few normal donor apheresis products
available, hence 4/6 HLA-matching to CLL patient cells was
difficult to achieve. Ultimately, two different normal donor
apheresis products were matched at 4/6 HLA loci to a single
CLL patient. One of these normal donor products failed to expand
at all when co-cultured with CD40-ligated CLL cells, a
phenomenon that was not observed among 14 different co-culture
experiments using UCB-derived T-cells. The second normal
donor product expanded and was able to be analyzed. IFN-c
ELISpot indicated that adult-derived PBMCs could recognize
alloantigen; however, there was no indication that CLL antigens
were recognized with any kind of specificity (Figure 6A). Further,
adult PBMC-derived T-cells primed by CLL-APCs were also
unable to mitigate significant lysis of CLL cells, indeed,
CLL-Specific Cord Blood CTL
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demonstrating a preferential lysis of the autologous CD8+ cells
rather than the CLL cells against which they had been primed
(Figure 6B). This lytic pattern was not observed among any of the
experiments performed with partially-HLA matched UCB T-cells.
Expanded UCB T-cells specific for alloantigens (GVH) can
be separated from T-cells specific for leukemic antigens
(GVL)
While the preceding data indicate that CLL-specific responses
can be generated from partially-HLA matched UCB T-cells, the
data also indicate that such responses are characterized by a high
background of alloreactivity as would be expected when priming
T-cells against an allogeneic stimulator. In order to render this
approach appropriate for clinical application, we developed a
GMP-compliant strategy for separating alloresponses (GVH) from
leukemia-specific responses (GVL). Ten days after the second
CLL-APC stimulation, bulk T-cells were stimulated with expand-
ed, irradiated CD8+ cells derived from the same patient as was the
leukemic clone. According to such a strategy, T-cells reactive
against shared alloantigens (as well as shared B and T lineage
antigens) respond and upregulate surface CD25 whereas T-cells
reactive only against leukemic (or at least B lineage-specific)
antigens remain CD25 negative. CD25+ T-cells (i.e. alloreactive
cells) were then magnetically depleted after which CD252 T-cells
were stimulated a third time with CLL-APC. A schematic of this
experimental design can be found in Figure 7. Figure 8 depicts the
results of this separation strategy (one of three independent
experiments). Figure 8A indicates few cells were CD25+ prior to
stimulation with autologous CD8+ cells. Figure 8B then shows the
significant fraction of cells that became CD25+ post allostimulation
(range 34.1%–49.1%). Figure 8C shows the efficiency by which
the CD25+ alloreactive cells can be depleted (range 95%–99%),
and Figure 8D shows that the formerly CD252 cells now
upregulate CD25 in response to CLL-specific stimulation (range
11.5%–18.7%). Because the CLL stimulators and the CD8+
stimulators are alloidentical, the T-cells that could not upregulate
CD25 following CD8+ cell stimulation but do upregulate CD25
following CLL cell stimulation must have a specificity for CLL (or
at least B-linage) antigens not expressed or presented by the CD8+
population. Figure 9A shows a representative ELISpot experiment
(one of three) in which the percentage of alloreactive cells is
Figure 4. UCB-derived CLL-specific T-cells form immunosynaptic complexes with CLL target cells. (A) UCB-derived CLL-specific T-cells
formed immunosynaptic complexes in 72% of conjugation events with CLL cells while naı¨ve T-cells could only form such complexes in 11% of
conjugations. Examples of synaptic complex (B) vs. non-synaptic complex (C) are shown. (D) indicates a typical analytic field in which synaptic
complexes are identified by white boxes and non-synaptic complexes by red boxes. In practice, at least 20 such field were evaluated for both naı¨ve
and expanded lymphocyte populations.
doi:10.1371/journal.pone.0051390.g004
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reduced from 76.0% (pre-separation unmanipulated) to 6.8%
(post-separation CLL-specific), with no CLL-specificity retained
among the depleted cells (post-separation allospecific). Figure 9B
shows a representative CTL assay (one of three) at E:T = 20:1 in
which lysis of autologous CD8+ targets by pre-separation CTL was
71.3% (versus 92.2% lysis of CLL targets) whereas CD8+ lysis by
CLL-specific CTL was only 11.0% (versus 51.5% of CLL targets).
Figure 9C demonstrates this principle over a range of E:T ratios,
demonstrating that, while unmanipulated and depleted allospecific
effectors lyse CD8+ alloidentical targets, the CLL-specific T-cells
no longer demonstrate lytic specificity for the CD8+ targets.
Conversely, Figure 9D indicates that the CLL-specific T-cells,
while they do not recognize CD8+ targets, still recognize and lyse
CLL targets with a high degree of specificity.
UCB T-cells stimulated by partially HLA-matched CLL-APC
control CLL in vivo and do not cause xenoGVHD
To demonstrate the ability of CLL-specific T-cells to function
appropriately in vivo without concomitant development of
xenoGVHD, we engrafted immunodeficient mice with a CLL
clone [29] against which CLL-specific T-cells had previously been
generated. Following engraftment, cohorts of 4 animals each were
treated with the 10710 CLL-specific CTL line (56106 per mouse),
while others were left untreated or treated with CTL lines
Figure 5. Partially HLA-matched UCB T-cells stimulated with CLL-APC preferentially react with and lyse the CLL cells against which
they were primed in an MHC Class I-Dependent Fashion. A. Normalized data taken from nine independent experiments indicate UCB CLL-
specific T-cells generated 20.3% more IFN-c ELIspots (p = 0.02) when complexed with the UCB CLL cells against which they had been primed than
when complexed with alloidentical stimulators. B. Raw data from representative experiment. C. These same cells could also mediate 79% more
specific killing (p = 0.00002) when complexed with the CLL cells against which they had been primed than when complexed with alloidentical targets.
D. Raw data from representative experiment. E. Lytic activity was abrogated by the W6/32 pan-MHC class I blocking antibody, demonstrating that
lysis is mediated in an antigen-specific fashion through MHC class I/TCR interaction. White bars: lytic activity in the presence of control antibody. Gray
bars: lytic activity in the presence of 1 mg/ml W6/32 antibody. Y-axis: percent specific lysis at E:T ratio = 50:1. For all five panels, error bars = +/2SD.
doi:10.1371/journal.pone.0051390.g005
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generated against a different leukemic clone (referred to as non-
specific CTLs). Six weeks later, mice were sacrificed and splenic B-
cell content examined by flow cytometry. As depicted by
Figures 10A and 10B, untreated or control treated mice exhibited
a splenic B-cell content of 19.3+/21.7% whereas mice treated
with CLL-specific T-cells exhibited a splenic B-cell content of
4.5+/23.5% (p = 0.01). The 4.5% splenic B-cell content of treated
mice was not statistically distinct from a cohort of mice (2.8+/
22.0%) that was not engrafted with CLL. At the end of the
experiment all the treated mice were healthy, exhibiting no
histological characteristics or behaviors associated with xe-
noGVHD (data not shown) within a time frame more than
sufficient for GVHD to develop [30].
Discussion
Recent work has demonstrated the vital role that both
allospecific and CLL antigen-specific T-cells play in the generation
of durable remission following nonmyeloablative HSCT [31]. Yet
the development of such effectors for active, specific immuno-
therapy of CLL might be significantly compromised by the ability
of CLL cells to efficiently suppress T-cell mediated immune
responses [20]–[][22]. Ramsay et al [23] have suggested that T-
cells derived from UCB grafts might be less susceptible to the
immunosuppressive effects of CLL cells, results that provided the
impetus for the present work. Here we demonstrate that
functional, CLL-specific T-cells can be generated by priming
UCB T-cells with partially HLA-matched, CD40-ligated CLL
cells. Importantly, these CLL-specific T-cells retain CTL function
when cultured with unmodified CLL targets. Functionality was
demonstrated by immune synapse assay, multiparametric intra-
cellular flow cytometry, IFN-c ELISpot, 51Cr release, and
suppression of CLL disease in a humanized in vivo mouse model.
Though functional comparison of UCB-derived T-cells with adult
PBMC-derived T-cells was technically challenging due to the
difficulty in finding sufficiently HLA-matched normal donor
products, the comparison performed did support the hypothesis
that UCB-derived T-cells possess an immunological advantage
allowing mitigation of CLL-mediated immunosuppression. In this
experiment, ELISpot data demonstrated that CD40-ligated CLL-
APC were unable to generate adult donor-derived T-cells with any
antigenic specificity, other than that against alloantigens. Further,
51Cr lytic data demonstrated that adult donor-derived PBMC
were unable to lyse CLL targets with the same efficiency as their
UCB-derived counterparts. While the ability of UCB-derived T-
cells to circumvent CLL-mediated immune suppression is signif-
Table 3. Summary of IFN-c ELISpot Results.
Assay Number IFN-c ELISpots per 50,000 Total Cells
CLL Targets CD8+ Targets Allogeneic Targets Unstimulated
1 198 140 N/A 78
2 63 83 N/A 42
3 18 8 N/A 0
4 279 210 38 1
5 280 236 31 1
6 287 318 137 1
7 362 262 341 2
8 404 338 92 2
9 276 218 N/A 1
doi:10.1371/journal.pone.0051390.t003
Table 4. Summary of 51Cr Lysis Results.
Assay Number Target Lysis at E:T =20:1
CLL Targets CD8+ Targets Allogeneic Targets (NK activity control)
1 54.9% 36.1% 50.4%
2 53.7% 39.0% 6.5%
3 61.4% 20.2% 43.6%
4 61.6% 36.9% 17.7%
5 55.2% 43.7% 3.5%
6 48.6% 7.0% 20.3%
7 51.9% 32.9% 19.7%
8 43.5% 25.0% 45.2%
9 42.8% 9.8% 28.9%
10 43.1% 23.9% 8.7%
11 92.2% 71.3% N/A
doi:10.1371/journal.pone.0051390.t004
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icant, the mechanism of circumvention is not understood. The
most obvious difference between UCB-derived T-cells and APB-
derived T-cells is that of the memory phenotype. Whereas T-cells
from the UCB cell product are almost entirely naı¨ve, T-cells in
peripheral circulation are predominantly of an effector memory
phenotype. Unpublished work from our laboratory has indicated
that the subcellular localization of the Src-family kinase p56/Lck is
significantly perturbed in NK cells following direct contact with
CLL cells, resulting in the downregulation of critical signaling
events at the immune synapse. Interestingly, a similar method of
immune suppression is employed by the HIV virulence factor nef,
the expression of which directs the localization of Lck to
extrasynaptic sites within HIV-infected CD4+ lymphocytes [32]–
[][34]. Data from the literature suggest that expression of Lck is
relatively low in UCB T-cells [35] and that, in contrast to memory
T-cells, Lck localization in naı¨ve T-cells is predominantly
cytoplasmic [36]. Given these data, we would hypothesize that
differential patterns of Lck expression and localization in naı¨ve,
UCB T-cells could account for the relative insensitivity of these
cells to a major CLL mechanism of immunosuppression.
Nevertheless, this hypothesis has yet to be formally investigated,
and in the absence of definitive mechanistic insight, the conclusion
that UCB T-cells are less susceptible to CLL-mediated immune
suppression than adult PBMC-derived T-cells necessarily remains
a preliminary finding.
The immunosuppressive effects of CLL upon T-cells are well-
documented in the literature [17]; [20]; [21]; [23]; however, there
is at least one report suggesting good immune recognition of CLL
by adult-derived PBMCs following co-culture with CD40-ligated
CLL-APC [37]. In this report, the authors generated CLL-APC by
incubation of primary CLL in 500 U/ml IL-4 in conjunction with
CD40 ligation, generating CLL-reactive CTL from CD4-depleted
bulk T-cells. In some cases, multiply-stimulated CTLs appeared to
lyse primary CLL with high efficiency; however, the CTLs almost
always lysed CD40-ligated CLL with a higher efficiency, the
authors provided no alloantigen control by which to determine the
presence of CLL-specific responses, and no comparison to cord
blood was provided. Given these important variables, it is difficult
to compare these data to the current work in a meaningful fashion.
Though we demonstrate lineage-specific immune recognition
above and beyond the background of alloantigenicity, the
background of allospecific responses is necessarily high when
UCB grafts are HLA-matched to the CLL patient product at only
4 of 6 HLA loci. The level of alloreactivity observed among the
unmanipulated CTL was clinically unacceptable, necessitating a
strategic modification of the protocol. We developed a GMP-
compliant protocol that could effectively separate alloreactive
Figure 6. In contrast to UCB-derived T-cells, adult-derived T-
cells do not demonstrate antigenic specificity against unli-
gated CLL targets. A. IFN-c ELISpot demonstrates no differences in
immune reactivity between adult T-cells primed by CLL-APC and CD8+
targets or CLL targets. Y axis = IFN-c ELISpots/50,000 cells. B. 51Cr killing
assay shows adult T-cells primed by CLL-APC mediate higher levels of
killing against the normal alloantigenic target (CD8+ cells) than against
the unligated CLL target. Y axis = percent specific killing. For both
panels, error bars =+/2SD.
doi:10.1371/journal.pone.0051390.g006
Figure 7. Flow chart schematic indicating the process of
separating GVH from GVL during the generation of CLL-
specific UCB T-cells.
doi:10.1371/journal.pone.0051390.g007
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CTL (GVH) from leukemia-specific CTL (GVL). This strategy
involved the stimulation of bulk CTL with non-leukemic cells
HLA-identical to the leukemic clone (i.e. patient normal cells)
followed by a CD25 magnetic depletion with a GMP-compliant
reagent. The remaining CTL were shown to be specific for the B-
lineage leukemic clone and non-reactive against the T-lineage cells
that served as stimulators for the CD25 depletion. Somewhat
related strategies have been described in the literature [38]–[][40],
most notably by Samarasinghe et al [40]. In this recent
publication, the authors used EBV-transformed LCLs to stimulate
alloreactive cells among HLA-mismatched normal donor prod-
ucts. There are several reasons why the use of bead-expanded,
irradiated CD8 cells might be preferable to the use of EBV-
transformed LCLs. Some of these reasons are technical (i.e. the
relative difficulty of generating LCL lines for every patient); some
are related to patient safety (i.e. issues encountered by the
introduction of EBV in the immunocompromised setting); and
some are regulatory (i.e. bead expansion of patient T-cells is
already part of an FDA approved clinical trial currently underway
at the MD Anderson Cancer Center). Further, Samarasinghe did
not demonstrate that their LCL-depleted T-cell product possessed
reactivity against primary leukemia [40] as we do here. More
practically, B-cell derived LCLs would not be appropriate for use
as stimulators in the setting of CLL since LCLs potentially share
important antigens with the B-lineage leukemic clone.
Recently, Porter et al described the successful application of
chimeric antigen receptor (CAR) technology to treat refractory
CLL [41]. In this study, patient T-cells were transduced with a
CAR construct recognizing the B-cell CD19 surface antigen and
then reinfused following ex vivo expansion. This exciting develop-
ment has reinvigorated the entire field and has engendered
cautious optimism that this and other cell therapy treatment
regimens might one day prove to be viable therapeutic options for
CLL and other important malignancies. It is worth noting,
however, that many other investigators previously failed to
produce similar results using essentially identical systems as that
used by Porter. Further, the reported results were of a very small
cohort for which a successful response was observed in 3 of only 4
treated patients. Given these caveats, we feel the translatability of
this approach on a large scale remains to be definitively
demonstrated. Additionally, the system described here offers a
significant advantage over CAR therapy in that that UCB T-cells
(which are eventually given to the recipient) do not have to
undergo transfection and potential genetic perturbation for
eventual tumor-specific functionality.
It would have been ideal to demonstrate in vitro separation of
GVL from GVH by using a panel of different cell types derived
from the patient. Unfortunately, this was not technically feasible.
Most patient leukodepletion products consisted almost entirely of
CLL cells, and it was only possible to generate substantial number
of autologous control CD8+ cells by the isolation and expansion of
very rare CD3+ cells. There is no analogous expansion protocol for
other cell types, nor can significant numbers of normal B-cells
typically be readily discerned from the neoplastic B-CLL
population. Further, most of the patient products released for
experimentation were derived from individuals whom were
already deceased or whom had been lost to follow-up, rendering
impossible or impractical the collection of cells from patients in
remission or the generation of autologous cell lines from patient
tissues. Though definitive conclusion that GVH and GVL have
Figure 8. Separation of Alloreactive T-cell activity (GVH) and leukemia-specific T-cell activity (GVL). (A) CD25 expression of bulk T-cells
prior to allostimulation. (B) CD25 expression of bulk T-cells post-allostimulation. (C) CD25 expression of allostimulated T-cells following depletion of
CD25+ cells. (D) CD25 depleted cells following third stimulation with CLL-APC.
doi:10.1371/journal.pone.0051390.g008
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been separated will require prospective validation of this strategy
using a panel of autologous hematopoietic cells isolated from
patients in remission, the absence of xenoGVHD in an animal
model supports this hypothesis. The analogy is not perfect given
that the murine alloantigens were not identical to the CLL
alloantigens that reacted non-specifically with the UCB graft T-
cells. Nonetheless, because of the significant cross-reactivity that
exists between human and mouse MHC, the experiment
demonstrates a highly focused specificity of response in vivo such
that all T-cell alloreactivity with the MHC class I H-2g7 murine
haplotype was lost.
Importantly, the depletion strategy described here might be
modified so as to be applicable not only to adoptive therapy, but to
a variety of other settings as well. The strategy is dependent solely
upon pretreatment of the therapeutic product with patient-derived
allostimulators and the ability to remove CD25+ cells in a GMP-
compliant fashion. The generation of allostimulators is straight-
forwardly accomplished by CD3/CD28 stimulation of patient T-
Figure 9. In Vitro Functional Analysis of Partitioned Leukemia-
Specific T-cells. (A) IFN-c ELISpot demonstrating the separation of
alloreactive T-cell activity from leukemia-specific T-cell activity. Black
bars – CLL stimulators. Dark gray bars – CD8+ stimulators. Light gray
bars – K562 stimulators (control for NK cell activity). White bars – No
stimulators. (B) 51Cr lytic assay demonstrating the separation of
alloreactive T-cell activity from leukemia-specific T-cell activity. Black
bars – CLL targets. White bars – CD8+ targets. X-axis: source of
responder cells. E:T ratio = 20:1. C. Demonstration of this principle over a
range of E:T ratios, indicating that, while unmanipulated and depleted
allospecific effectors lyse CD8+ alloidentical targets, the CLL-specific T-
cells no longer demonstrate lytic specificity for the CD8+ targets. Light
gray lines/triangles = unmanipulated effectors. Dark gray lines/squar-
es = partitioned allospecific effectors. Black lines/diamonds= CLL-spe-
cific effectors. Targets consisted of non-leukemic but HLA-identical
CD3+CD8+ cells. D. Conversely, the CLL-specific T-cells do not recognize
alloidentical CD8+ targets but still recognize and lyse CLL targets with a
high degree of specificity. Black lines/diamonds = CLL targets. Gray
lines/squares =CD3+CD8+ targets. Effectors consisted of post-separa-
tion CLL-specific T-cells. For all four panels, error bars = +/2 SD.
doi:10.1371/journal.pone.0051390.g009
Figure 10. In Vivo Functional Analysis of Partitioned Leukemia-
Specific T-cells. A. Administration of CLL-specific T-cells in vivo to CLL-
engrafted mice resulted in a reduction of splenic B-cell burden from
19.3% in untreated or control-treated mice to 4.5% (p= 0.01) among
mice treated with CLL-specific T-cells This was statistically indistin-
guishable from the 2.8% splenic B-cell content of non-CLL engrafted
mice. B. Representative flow cytometry plot of splenic CD19+ cells.
Dashed line/unfilled= isotype control. Thick black line/unfilled =CLL
engrafted and treated with CLL-specific effectors. Thin black line/gray
filled =CLL engrafted but untreated.
doi:10.1371/journal.pone.0051390.g010
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cells, and efficient removal of CD25+ cells is accomplished by the
use of magnetic separation technologies, two techniques that are
well within the routine capabilities of most academic cell therapy
centers. Hence this separation strategy, in one of several different
forms, might ultimately be useful in the setting of allogeneic
hematopoietic stem cell transplantation, solid organ transplanta-
tion, and regenerative medicine applications.
In summary, we describe a novel strategy by which UCB-
derived, CLL-specific T-cells might be generated for therapeutic
applications. Despite the ability of CLL to induce T-cell
immunosuppression, UCB-derived T-cells appear to retain func-
tionality when co-cultured and assayed with unmanipulated CLL
targets. T-cell specificity encompassed both alloantigens and CLL-
specific antigens; however, alloreactive T-cells were tentatively
separated from leukemia-specific T-cells by means of a straight-
forward, GMP-compliant strategy. The tentative ability to
separate alloreactive T-cells (GVH) from leukemia-specific T-cells
(GVL) in vitro is a crucial component of this particular strategy but
might also be applicable to other settings as well. T-cell allotherapy
for patients with CLL as indicated by our results could be provided
under several clinical scenarios including 1) as a singular cellular
therapy in the setting of lymphodepleting chemotherapy [42]; 2) as
a third party source of tumor reactive T-cells in the setting of
traditional, matched-related or matched-unrelated HSCT; or 3) as
an adjunct to double UCB HSCT. In the latter scenario, one
could conceive of expanding a fraction of a single UCB unit to
generate tumor-specific T cells and administering as a DLI in the
peri-HSCT, minimal residual disease setting. The data support the
further development of this novel procedure as a therapeutic
modality for CLL in conjunction with UCBT as a means of
preventing or treating relapsed disease.
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